Hybio Pharmaceutical Co., Ltd.
300199
Classement en actions
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Prix de l'action
$3.69
Capitalisation boursière
$3.11B
Changement (1 jour)
-7.75%
Changement (1 an)
21.56%
Pays
CN
Échange Hybio Pharmaceutical Co., Ltd. (300199)
Catégorie
Healthcare
Nombre d'actions en circulation pour Hybio Pharmaceutical Co., Ltd. (300199)
Nombre d'actions en circulation au June 2026: 883.24M
Selon les derniers rapports financiers et le cours de l'action de Hybio Pharmaceutical Co., Ltd., le nombre actuel d'actions en circulation est de 883.24M. À la fin de December 2024, l'entreprise avait 868.27M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Hybio Pharmaceutical Co., Ltd. (300199) de 2007 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2026 (TTM) | 883.24M | -3.39% |
| 2025 | 914.25M | 5.30% |
| 2024 | 868.27M | -2.00% |
| 2023 | 885.99M | 0.31% |
| 2022 | 883.24M | 0.00% |
| 2021 | 883.24M | 0.00% |
| 2020 | 883.24M | 0.00% |
| 2019 | 883.24M | -3.74% |
| 2018 | 917.60M | 0.19% |
| 2017 | 915.89M | 3.54% |
| 2016 | 884.62M | -1.50% |
| 2015 | 898.06M | -0.54% |
| 2014 | 902.96M | 11.19% |
| 2013 | 812.07M | -0.53% |
| 2012 | 816.35M | 9.05% |
| 2011 | 748.60M | 23.95% |
| 2010 | 603.97M | 2.47% |
| 2009 | 589.43M | 26.14% |
| 2008 | 467.27M | 0.00% |
| 2007 | 467.27M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| 434.78M | -50.77% |
DE
|
|
| 434.78M | -50.77% |
DE
|
|
| 1.56B | 76.91% |
JP
|
|
| 233.66M | -73.55% |
CH
|
|
| 2.40B | 171.65% |
IN
|
